ABBV · News · 20260917N

Aesthetic Care Demand Trends

AbbVie Inc. · 2026-09-17 · Importance 31 · Surprise 42

Allergan Aesthetics announced two single-center clinical studies evaluating targeted skincare regimens in individuals taking medical weight loss medications, including GLP-1 receptor agonists. The studies assess skincare alone and in combination with DiamondGlow dermabrasion treatments. The data will be presented at the 2026 Science of Skin Summit on September 17, 2026, supporting AbbVie’s Aesthetics portfolio targeting skin-quality needs associated with medical weight loss.

Key facts

• Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs). source
• The two studies are single-center clinical studies. source